Crestline Management, LP - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 167 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.3%.

Quarter-by-quarter ownership
Crestline Management, LP ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$1,736,787
+22.7%
63,110
+51.2%
0.20%
+36.5%
Q2 2023$1,415,797
+30.0%
41,727
+37.9%
0.15%
+14.7%
Q1 2023$1,088,827
-32.8%
30,262
-16.8%
0.13%
-45.8%
Q4 2022$1,620,788
+44.2%
36,365
-9.1%
0.24%
+56.6%
Q3 2022$1,124,000
+9.4%
39,993
+5.0%
0.15%
+13.4%
Q2 2022$1,027,000
-6.0%
38,093
+18.7%
0.13%
+2.3%
Q1 2022$1,093,00032,0950.13%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q4 2022
NameSharesValueWeighting ↓
Kynam Capital Management, LP 2,600,000$88,218,00012.13%
Octagon Capital Advisors LP 759,898$25,783,3393.59%
TSP Capital Management Group, LLC 251,895$8,546,8003.08%
ACUTA CAPITAL PARTNERS, LLC 122,343$4,151,0982.81%
5AM Venture Management, LLC 310,270$10,527,4612.62%
COMMODORE CAPITAL LP 631,665$21,432,3932.41%
RTW INVESTMENTS, LP 3,463,201$117,506,4102.24%
Eversept Partners, LP 785,740$26,660,1582.23%
Redmile Group, LLC 1,696,004$57,545,4162.21%
Affinity Asset Advisors, LLC 87,031$2,952,9621.03%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders